EZZ Life Science Holdings Ltd. (EZZ) AI Stock Analysis

• Market Cap: AU$110.39M
• Dividend Yield: 1.82%
• Average Volume (3M): 120.88K
• Price to Earnings (P/E): 11.4
• Beta (1Y): -0.20
• Revenue Growth: 71.65%
• EPS Growth: 152.89%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.07
• Shares Outstanding: 47,173,200
• 10 Day Avg. Volume: 92,083
• 30 Day Avg. Volume: 120,876
• PEG Ratio: 0.00
• Price to Book (P/B): 59.13
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 117.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$3.00
• Price Target Upside: 36.36% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 78 Outperform
• Price Target: AU$2.50 ▲(13.64%Upside)

EZZ Life Science Holdings Ltd. presents a compelling investment opportunity due to its strong financial performance and healthy valuation metrics. The company's efficient cash flow management and low leverage increase its financial stability. Technical indicators suggest a potential for price appreciation, although the neutral RSI and low stochastic indicate current market caution. The absence of earnings call data and corporate events does not detract from the company's solid fundamentals.

EZZ Life Science Holdings Ltd. Business Overview & Revenue Model

Company Description

EZZ Life Science Holdings Limited provides skin care and consumer health products in Australia, New Zealand, Mainland China, and internationally. The company operates in two segments, Brought in Lines and Company Owned products. It is involved in the wholesale distribution of EAORON branded skin care products to pharmacies, supermarkets, and specialist retailers, as well as grocery retailers. The company also designs, develops, produces, distributes, and sells consumer health products, including vitamins and dietary supplements, sports nutrition, weight management and wellbeing, herbal/traditional, and paediatric products under the EZZ brand through its e-commerce platforms and stores, such as Tmall Global. EZZ Life Science Holdings Limited was incorporated in 2015 and is based in Silverwater, Australia.

How the Company Makes Money

EZZ Life Science Holdings Ltd. generates revenue primarily through the sale of its health and wellness products. The company markets its products through multiple channels, including retail, online platforms, and third-party distributors, allowing it to reach a broad customer base. Key revenue streams include the sale of nutritional and dietary supplements, skincare products, and other consumer health solutions. EZZ also leverages strategic partnerships and collaborations with retailers and distributors to expand its market presence and enhance its product offerings, contributing to its overall earnings.

EZZ Life Science Holdings Ltd. Financial Statement Overview

Summary

EZZ Life Science Holdings Ltd. demonstrates strong financial health with robust revenue growth and profit margins. The company maintains a conservative leverage strategy and displays strong cash generation capabilities. Overall, EZZ Life Science is well-positioned for growth with strong fundamentals.

Income Statement

EZZ Life Science Holdings Ltd. demonstrates strong revenue growth, with a 78.9% increase in total revenue from 2023 to 2024. The gross profit margin is robust at 74.2%, indicating efficient cost management. Net profit margin stands at 10.5%, showing healthy profitability, though there's room for improvement in converting revenue to net income. EBIT and EBITDA margins are solid at 14.6% and 15.6%, respectively, reflecting operational efficiency.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.01, showcasing a conservative leverage strategy. Return on Equity (ROE) is strong at 32.7%, indicating effective use of shareholders' equity. The equity ratio is high at 83.5%, highlighting financial stability and low financial risk. Overall, the balance sheet reflects a strong financial position with minimal debt.

Cash Flow

EZZ Life Science Holdings Ltd. shows a significant increase in free cash flow, with a growth rate of 46.6% from the previous year. The operating cash flow to net income ratio is 0.88, indicating efficient cash generation relative to reported earnings. The free cash flow to net income ratio is 0.82, suggesting that the company's operations are generating ample cash relative to net income.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	75.03M	66.44M	37.14M	15.02M	22.29M	17.32M
Gross Profit	58.04M	50.95M	27.20M	7.51M	12.46M	3.56M
EBITDA	13.45M	10.38M	5.09M	1.90M	2.76M	2.30M
Net Income	9.02M	6.96M	3.63M	1.31M	2.03M	1.59M
Balance Sheet
Total Assets	29.74M	25.55M	17.64M	14.27M	12.04M	11.63M
Cash, Cash Equivalents and Short-Term Investments	19.89M	19.02M	13.83M	10.46M	8.85M	8.41M
Total Debt	478.59K	123.86K	478.59K	104.57K	79.01K	32.00K
Total Liabilities	5.70M	4.23M	3.06M	2.88M	1.93M	3.78M
Stockholders Equity	24.04M	21.32M	14.58M	11.39M	10.11M	7.85M
Cash Flow
Free Cash Flow	7.40M	5.73M	3.91M	1.89M	237.42K	2.88M
Operating Cash Flow	7.97M	6.14M	4.01M	1.90M	253.53K	2.97M
Investing Cash Flow	-425.39K	-441.17K	-101.78K	-13.18K	-16.12K	-91.20K
Financing Cash Flow	-1.03M	-582.45K	-761.72K	-277.36K	5.44M	-122.25K

EZZ Life Science Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EZZ, the sentiment is Negative. The current price of 2.2 is below the 20-day moving average (MA) of 2.35, above the 50-day MA of 1.87, and below the 200-day MA of 2.34, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 50.96 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EZZ.

EZZ Life Science Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EZZ	78 Outperform	AU$110.39M	11.38	45.86%	1.82%	71.65%	152.89%
Sector *	52 Neutral	$7.51B	0.24	-62.67%	2.30%	16.09%	0.95%
INNMF		$81.81M	―	-41.60%	―	―	―
IUGND		$61.44M	―	-99.05%	―	―	―
PRNAF		$90.11M	―	-154.88%	―	―	―
RCE	40 Underperform	AU$92.28M	―		―	―	-33.01%
ALA	40 Underperform	AU$104.59M	―	-85.35%	―	315.11%	51.16%

EZZ Life Science Holdings Ltd. Corporate Events

EZZ Life Science Holdings: Strategic Investor Communication

EZZ Life Science Holdings Ltd. has released a presentation document outlining its current position and future outlook. The document emphasizes the company’s caution regarding forward-looking statements and advises investors to conduct their own assessments. This release highlights the company’s commitment to transparency and careful communication with its stakeholders, reflecting a strategic approach to managing investor relations and market expectations.

EZZ Life Science Expands into US Market with EZZDAY Launch

EZZ Life Science Holdings Limited has launched its US-focused brand, EZZDAY, marking a significant step in its international expansion strategy. The launch includes FDA-registered health supplements tailored for the US market, supported by local manufacturing to meet consumer preferences and ensure supply chain resilience. The company has initiated sales through a Shopify store, with plans to expand to Amazon and engage in influencer marketing to boost brand awareness. This strategic entry into the US, one of the largest health supplement markets, aims to establish a sustainable presence and capitalize on the growing demand in key health categories.

EZZ Life Science Holdings Announces Dividend Distribution

EZZ Life Science Holdings Ltd. has announced a dividend distribution of AUD 0.02 per ordinary fully paid share, covering the six-month period ending December 31, 2024. The ex-dividend date is set for May 16, 2025, with the record date on May 19, 2025, and payment scheduled for June 17, 2025. This announcement reflects the company’s financial health and commitment to returning value to shareholders, potentially strengthening its market position and investor confidence.

EZZ Life Science Declares Interim Dividend for 2024

EZZ Life Science Holdings Limited has announced a fully franked interim dividend of $0.020 per share for the half year ending 31 December 2024. This decision reflects the company’s commitment to rewarding shareholders and may enhance investor confidence. The dividend will be paid on 17 June 2025, with the ex-dividend date set for 16 May 2025 and the record date on 19 May 2025.

EZZ Life Science Reports Strong Q3 Performance and Strategic Growth Initiatives

EZZ Life Science Holdings Limited reported strong operational performance for the quarter ending March 31, 2025, despite a decline in customer receipts due to seasonal factors and reduced digital advertising. The company achieved a positive cash inflow of $1.5 million and maintained a record cash reserve of $21.1 million. EZZ launched two new products and upgraded three existing ones, enhancing its competitive position. The company expanded its domestic distribution and made strategic progress in entering the US market. EZZ also increased brand visibility through sponsorships and strengthened its presence in China, positioning itself for long-term growth.